NASDAQ:NCNA

NuCana (NCNA) Stock Price, News & Analysis

NuCana logo
$0.88 +0.02 (+1.96%)
Closing price 03:55 PM Eastern
Extended Trading
$0.87 -0.01 (-0.80%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About NuCana Stock (NASDAQ:NCNA)

Advanced

Key Stats

Today's Range
$0.77
▼
$0.94
50-Day Range
$0.88
▼
$1.40
52-Week Range
$0.77
▼
$4.55
Volume
43,416 shs
Average Volume
70,720 shs
Market Capitalization
$3.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

NuCana is a clinical-stage biopharmaceutical company based in Edinburgh, Scotland, that develops investigational medicines for cancer. Its research focuses on nucleotide analogues, a class of compounds used in some cancer treatments.

The company’s ProTide platform is designed to improve how these compounds enter cells and become active. NuCana’s development programs have included NUC-3373, an investigational fluoropyrimidine, and NUC-7738, an investigational adenosine analogue, as well as NUC-1031, an earlier candidate.

NuCana’s work is centered on developing and evaluating potential cancer therapies; its drug candidates are investigational and have not been established as approved treatments.

AI Generated. May Contain Errors.

NuCana Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
21st Percentile Overall Score

NCNA MarketRank™: 
1.064943671305 of 5 stars

NuCana scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NuCana has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    NuCana has only been the subject of 1 research reports in the past 90 days.

  • Read more about NuCana's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NuCana is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NuCana is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NuCana has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.86% of the float of NuCana has been sold short.
  • Short Interest Ratio / Days to Cover

    NuCana has a short interest ratio ("days to cover") of 4.88.
  • Change versus previous month

    Short interest in NuCana has recently decreased by 3.99%, indicating that investor sentiment is improving.
  • Dividend Yield

    NuCana does not currently pay a dividend.

  • Dividend Growth

    NuCana does not have a long track record of dividend growth.

  • News Sentiment

    NuCana has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for NuCana this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    3 people have added NuCana to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NuCana insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NuCana's insider trading history.
Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NCNA Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
NuCana plc Sponsored ADR
NuCana Appoints Ian Webster as Chief Financial Officer
See More Headlines

NCNA Stock Analysis - Frequently Asked Questions

NuCana's stock was trading at $3.60 at the start of the year. Since then, NCNA shares have decreased by 75.3% and is now trading at $0.89.

NuCana PLC Sponsored ADR (NASDAQ:NCNA) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($2.65) by $2.18.

NuCana shares reverse split before market open on Friday, August 8th 2025.The 1-200 reverse split was announced on Friday, July 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

NuCana (NCNA) raised $100 million in an IPO on Thursday, September 28th 2017. The company issued 6,667,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NuCana investors own include NVIDIA (NVDA), Plug Power (PLUG), Palantir Technologies (PLTR), Pinterest (PINS), Advanced Micro Devices (AMD), PayPal (PYPL) and Tesla (TSLA).

Company Calendar

Last Earnings
11/12/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:NCNA
CIK
1709626
Fax
N/A
Employees
11
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
($4.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.71 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.68%
Return on Assets
-39.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.73
Quick Ratio
4.73

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.71 per share
Price / Book
0.11

Miscellaneous

Outstanding Shares
4,160,000
Free Float
2,863,000
Market Cap
$3.66 million
Optionable
Not Optionable
Beta
2.39

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:NCNA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners